Interim Safety Results of Amlitelimab (anti-OX40 ligand antibody) in Participants With Moderate-to-Severe Atopic Dermatitis From the RIVER-AD Phase 2/3 Ongoing Open-Label Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s602, 2025. DOI: 10.25251/mq5bgn88. Disponível em: https://skin.dermsquared.com/skin/article/view/3885. Acesso em: 30 apr. 2026.